Screener
Vertex Pharmaceuticals VRTX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's other income, net (note 6)?
- Vertex Pharmaceuticals (VRTX) reported other income, net (note 6) of $24.3M in Q2 2026.
- How has Vertex Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Vertex Pharmaceuticals's other income, net (note 6) increased by 84.1% year-over-year, from $13.2M to $24.3M.
- What is the long-term trend for Vertex Pharmaceuticals's other income, net (note 6)?
- Over 3 years (2021 to 2024), Vertex Pharmaceuticals's other income, net (note 6) has grown at a 160.0% compound annual growth rate (CAGR), from $4.9M to -$86.1M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Vertex Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude